Medicine and Dentistry
Lung Cancer
100%
Malignant Neoplasm
89%
Osteosarcoma
85%
Overall Survival
77%
Neoplasm
73%
Nivolumab
64%
Ipilimumab
64%
Diseases
62%
Connective Tissue Cancer
49%
Cancer
47%
Lung Metastasis
42%
Biological Product
42%
Interleukin 11 Receptor
42%
Rheumatoid Arthritis
42%
Inflammatory Arthritis
42%
Non Small Cell Lung Cancer
42%
Hazard Ratio
42%
Surgery
37%
Antirheumatic Agent
37%
Arm
36%
Systemic Therapy
32%
Lung
31%
Adverse Event
30%
Progression Free Survival
30%
Immune Checkpoint Inhibitor
27%
Metastatic Carcinoma
26%
Advanced Cancer
26%
Neoadjuvant Therapy
26%
Immunity
25%
Quality Improvement
23%
Adolescence
23%
Primary Tumor
22%
Light Chain
21%
BRCA1
21%
Nerve Sheath Tumor
21%
Prospective Study
21%
Pleura Metastasis
21%
Pazopanib
21%
Preoperative Chemotherapy
21%
Internal Medicine
21%
Early Cancer
21%
Retroperitoneum
21%
Veterans Affairs
21%
Phyllodes Tumor
21%
Talazoparib
21%
Sclerosis
21%
Disease Modifying Antirheumatic Drug
21%
Paclitaxel
21%
Heat Shock Protein 27
21%
Surgical Mortality
21%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
72%
Nivolumab
64%
Osteosarcoma
64%
Ipilimumab
64%
Older Adults
53%
Overall Survival
49%
Chemotherapy
47%
Disease-modifying Antirheumatic Drugs (DMARDs)
42%
Lung Metastasis
42%
Interleukin-11 Receptor
42%
Surgical Outcomes
42%
Enhancer of Zeste Homolog 2 (EZH2)
42%
Rheumatoid Arthritis
42%
Signaling Axis
42%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
42%
Therapeutic Strategies
42%
Clinical Outcomes
32%
Neoadjuvant
31%
Computed Tomography
30%
High Risk
28%
Pathologic
26%
Neoadjuvant Chemotherapy
26%
Neoadjuvant Therapy
26%
Confidence Interval
25%
Clinical Activity
25%
Progression-free Survival
25%
Clinical Benefit
25%
Clinical Efficacy
24%
Advanced Cancer
23%
Cancer Treatment
23%
Systemic Therapy
23%
Resection
23%
Tumor
22%
Immune Checkpoint Inhibitors
22%
Medicine Evaluation
21%
Preoperative Chemotherapy
21%
Resection Specimen
21%
BRCA1, BRCA2
21%
Pazopanib
21%
Retroperitoneum
21%
Phyllodes Tumor
21%
Single Center
21%
Talazoparib
21%
Clinical Safety
21%
Older Patients
21%
Early Cancer
21%
Undifferentiated Pleomorphic Sarcoma of Bone
21%
Phase 1b Study
21%
Colitis
21%
Heat Shock Protein 27 (HSP27)
21%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
90%
Osteosarcoma
64%
Diseases
54%
Neoplasm
51%
Overall Survival
45%
Chemotherapy
45%
Non Small Cell Lung Cancer
44%
Lung Metastasis
42%
Interleukin 11 Receptor
42%
Inflammatory Arthritis
42%
Biological Product
42%
Rheumatoid Arthritis
42%
Antirheumatic Agent
32%
Lung Cancer
26%
Advanced Cancer
26%
Selinexor
21%
Pazopanib
21%
Pleura Metastasis
21%
Nivolumab
21%
Talazoparib
21%
QT Prolongation
21%
Heat Shock Protein 27
21%
Disease Modifying Antirheumatic Drug
21%
Solid Malignant Neoplasm
21%
Phosphoglycerate Dehydrogenase
21%
Ovary Cancer
21%
Desmoplastic Small Round Cell Tumor
21%
Sclerosis
21%
Malignant Pleura Effusion
21%
Paclitaxel
21%
Well Differentiated Liposarcoma
21%
Survival Prediction
21%
Effusion
21%
Ipilimumab
21%
Fragility Fracture
21%
Immune Checkpoint Inhibitor
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
14%
Primary Tumor
13%
Recurrence Free Survival
10%
Metastasis
10%
Monotherapy
10%
Lactate Dehydrogenase
10%
Cohort Study
8%
Interleukin 11
8%
Adverse Event
8%
Progression Free Survival
8%
Phase II Trials
7%
Tumor Necrosis Factor Inhibitor
7%
Clinical Trial
7%
Life Expectancy
5%